CG
AST

Cutler Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Cutler Group’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,000
Closed -$18K – 7755
2017
Q1 		$18K Buy
+10,000
New +$38.9K ﹤0.01% 3472

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cutler Group's AST Position: Q2 2017 in Review

Cutler Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2017, closing a stake of 2,984 shares — an estimated $10K sold.

Cutler Group first reported a position in AST in Q4 2015 and held it in 6 quarters. The position peaked at $10K in Q1 2017. 64 funds tracked by Wall St. Rank hold AST as of Q2 2017.

  • Cutler Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2017 after selling out during the quarter.
  • Cutler Group sold 2,984 Asterias Biotherapeutics Inc. Series A shares in Q2 2017, an estimated $10K.
  • Cutler Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2015 and held it in 6 quarters.
  • Cutler Group's Asterias Biotherapeutics Inc. Series A position peaked at $10K in Q1 2017.
  • 64 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2017.

Based on Cutler Group's 13F filing for Q2 2017, filed 11 Jul 2017.